resistanceto antibiotics in intensive care units continue to grow.
-resistance: what we need in the immediate future. Under this title, specialistsintensivistas held a meeting in Bilbao sponsored by AstraZeneca.
-the meetingIt was led by Dr. Javier Garau disease serviceInfectious Hospital mutual of Terrassa.
Bilbao, 2011-June AstraZeneca has sponsored a scientific meeting under thetitle resistance: what we need in the immediate future.
meetingscientific, addressed to professionals of intensive care, told with theparticipation of experts in the field of infections as Dr. JavierGarau, in the service of infectious diseases of the Mutua Hospital in Terrassaor Dr. Seamus O´Brien, Clinical Director of AstraZeneca infections.
resistanceantibiotics are a daily problem they face thehealth professionals in hospitals, where the possibilities that thepatients contract infections caused by a pathogen resistance areincreasing more and more.
according to Dr.Garau, is in special units such as intensive care where theresistance to antibiotics and infections become moreobstacle. These patients are facing constant exposure ofinfections while inevitably are in a situation of highrisk ”. The previous exposure to antibiotics and the number of day ofhospital stay the main risk factors for infectionsin hospitalized patients, Dr. Garau pointed out that the use of theantibiotics must be rational. Only to be used when they are actuallynecessary and the appropriate duration ”.
resistancetreatments for infections are, in the words of the own Garau,as a result of the coping mechanisms that the bacteria have been ablefinding. Since the almost 40 years ago made the use of theantibiotics, certain bacterial species have become resistant to thesame due to the accumulation in the time that they have learned toprotected. For this reason, now practitioners face moreeasily to bacteria multi-resistencias.
Furthermore,Or ’ Brien emphasized the investigative role of AstraZeneca in the area of theinfections, in which the company has a broad portfolio of products indevelopment.
about AstraZeneca.
AstraZeneca isan innovative biopharmaceutical global focused primarily on theDiscovery, development and commercialization of prescription drugs,leader in the treatment of gastrointestinal, cardiovascular, neuroscience,respiratory and inflammation, oncology and infectious diseases.
